J. Goldman & CO LP Aurinia Pharmaceuticals Inc. Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $1.95 Million - $2.59 Million	-273,003 Reduced 70.62%	113,550 $1.02 Million
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $1.29 Million - $2.04 Million	-165,854 Reduced 30.02%	386,553 $3 Million
Q2 2023 Aug 14, 2023	BUY	$8.96 - $11.69 $4.95 Million - $6.46 Million	552,407 New	552,407 $5.35 Million
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $1.26 Million - $1.56 Million	-97,382 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$13.19 - $16.66 $1.05 Million - $1.33 Million	-79,816 Reduced 45.04%	97,382 $1.43 Million
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $417,726 - $542,274	29,584 Added 20.04%	177,198 $2.88 Million
Q1 2020 May 15, 2020	SELL	$11.34 - $21.46 $55,611 - $105,239	-4,904 Reduced 3.22%	147,614 $2.14 Million
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $591,769 - $3.27 Million	152,518 New	152,518 $3.09 Million

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.